SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is currently a hot topic, fueled by significant institutional ETF inflows and circulating rumors of geopolitical developments leading to asset tokenization. The community is actively discussing a potential short squeeze and impending regulatory clarity, driving widespread bullish sentiment amid expectations of a supply shock.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to escalating short interest and high borrowing fees, igniting strong community efforts for a short squeeze. Major talking points include the breaking of the key $5 price threshold, which is attracting broader institutional investor interest, and intense speculation around a potential buyout for its promising cancer treatment pipeline.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings Inc. (ONDS) is a major discussion point following recent announcements of new autonomous system orders and a strategic move to West Palm Beach, Florida, signaling a focus on the defense and security technology sector. Community sentiment is largely bullish, with many drawing parallels to explosive past tech runs and anticipating further growth from upcoming business updates, though some investors are eyeing potential pullbacks after its recent ascent.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending amid market debate following Novo Nordisk's oral GLP-1 approval, sparking discussions over competitive pressures versus broader market validation for the expanding obesity drug sector. Community sentiment is divided, with some investors frustrated by recent price action and a perceived lack of immediate M&A, while others highlight VKTX's "best in class" pipeline and strong Phase 3 progress, anticipating a significant partnership or buyout, especially ahead of the upcoming JPM conference. This positions VKTX at a pivotal moment for its strategic future in the highly competitive weight-loss landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly anticipates the Biologics License Application resubmission for its Duchenne Muscular Dystrophy treatment, deramiocel, following promising Phase 3 HOPE-3 data. While many longs highlight the statistically significant clinical improvements and dismiss recent dips as short-driven manipulation or tax-related selling, some investors express concern over the delayed submission and potential regulatory hurdles. Broader discussions also revolve around the long-term value of the company's innovative StealthX platform and a potential short squeeze, emphasizing its strong financial position and the impact of patient advocacy.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to high anticipation for its CES 2026 keynote, where the company is expected to unveil new AI-focused Core Ultra Series 3 processors and highlight its 18A manufacturing advancements, boosted by Nvidia's significant equity investment. While many community members are optimistic about Intel's turnaround and long-term prospects, there's notable frustration over persistent "dumping" by institutional players that frequently negates pre-market gains, sparking intense debate about market manipulation.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy ($MSTR) is trending as its stock price fails to keep pace with an upward move in Bitcoin ($BTC), generating significant community debate. Shareholders are voicing frustration over what they perceive as unusual price action and dilution by CEO Michael Saylor, while also monitoring the upcoming MSCI index decision.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus is trending with significant volume after announcing the development of an additive-manufactured fuel tank for its Vigoride-7 orbital service vehicle, driving community discussion around a potential short squeeze given its low float. While many are optimistic about its prospects within the active space sector, some investors caution about the company's history of capital raising and prior reverse splits.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending with significant bullish momentum, as the community actively discusses a potential short squeeze and a breakout past crucial resistance levels. This heightened interest is fueled by the company's integral role in space infrastructure and defense, anticipation of new contracts, and a broader sector revaluation, positioning RDW as an undervalued play in the expanding space economy.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is a major point of discussion, driven by the announcement of a $2 billion revolving credit facility and its new high-density, liquid-cooled server systems essential for AI infrastructure. The community is sharply divided; bulls emphasize the company's pivotal role in anticipated xAI data center expansions and deeply undervalued status, especially as tax-loss harvesting periods conclude. Conversely, skeptics remain critical of management's past performance and the ongoing need for external financing, fueling intense debate on its near-term direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Liminatus Pharma, Inc. hit a record high on Wednesday after the company declared it had restored compliance with Nasdaq listing standards.The stock closed at $12.71, up 132.8% on Wednesday, with after-hours trading pushing the price further up 69.2% to $21.50.Liminatus received formal confirmation from Nasdaq on June 3, confirming the Nasdaq Listing Rule 5250(c)(1), which requires timely submission of reports to the U.S. Securities and Exchange Commission (SEC).&nbsp;The matter is now considered closed.Earlier on May 29, the company received a notice for not submitting its quarterly report on Form 10-Q for the quarter ended March 31, 2025, promptly.&nbsp;Liminatus submitted the delayed report on June 2, reinstating its SEC reporting compliance.Liminatus came public in early May following a Special Purpose Acquisition Company (SPAC) merger.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.While pointing out that the Liminatus Pharma stock held support, one user said they expected the rally to continue to the next day due to the relatively small float size of 150,000.<stembedurl>https://stocktwits.com/WealthQuest/message/616859995</stembedurl>Another user suggested that the company was preparing to spike to $35.<stembedurl>https://stocktwits.com/View2021/message/616842522</stembedurl>Since its May listing, the stock&nbsp;has risen 9.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance 

The company had previously faced a notice for delayed filings but has since rectified the issue.

Equity

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Liminatus Pharma Inc. - Ordinary Shares - Class A

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

LIMN
Liminatus Pharma Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest LIMN News

LIMNLiminatus Pharma Inc.